Publications by authors named "David W Henry"
Gender disparity exists in leadership roles within healthcare. While the majority of the healthcare workforce is comprised of women, significantly fewer women occupy leadership positions, particularly at executive and board levels. As the field of oncology pharmacy continues to rapidly expand and evolve, an assessment of the current state of women in oncology pharmacy leadership roles is vital to the growth and development of the profession.
View Article and Find Full Text PDFIntroduction: Due to enhanced T-cell activity, immune checkpoint inhibitors cause immune-related adverse effects. Corticosteroids are the mainstay of immune-related adverse effect management but the optimal strategy has not been determined, putting patients at risk for steroid-related adverse effects and potentially decreased efficacy of immunotherapy. This study aims to characterize the use of corticosteroids for the management of immune-related adverse effect.
View Article and Find Full Text PDFArticle Synopsis
- This study aimed to explore the feasibility and effectiveness of combining low-dose anti-angiogenic chemotherapy (vinblastine and celecoxib) with standard treatment for patients with metastatic Ewing sarcoma (ES).
- Out of 35 enrolled patients, 90% completed most of the planned treatment, with manageable side effects, though some experienced serious toxicities, particularly those who had prior pulmonary irradiation.
- The results showed a 24-month event-free survival rate of 35% overall, but it was notably higher (71%) for patients with isolated pulmonary metastases, indicating potential benefits despite concerns over increased toxicity in irradiated areas.
Study Objectives: To assess the effectiveness of prophylactic albumin for the prevention of ifosfamide-induced encephalopathy (IIE), and to describe risk factors for IIE and investigate the predictive potential of a novel risk-stratification model for IIE.
Design: Retrospective analysis.
Setting: Single academic medical center.
Article Synopsis
- The study investigates how obesity affects outcomes in pediatric patients diagnosed with acute lymphoblastic leukemia (ALL), specifically looking at event-free survival and relapse rates.
- Data from over 4,000 patients diagnosed between 1988 and 1995 reveals that obese patients have a lower 5-year event-free survival rate (72%) compared to nonobese patients (77%), along with a higher risk of relapse.
- The findings highlight that obesity at diagnosis is a significant predictor of poorer outcomes in preteens and adolescents with ALL, regardless of chemotherapy treatment specifics.
Today's obesity pandemic began in the United States, spread to Western Europe and other developed regions, and is emerging in developing countries. Its influences on outcomes of childhood cancer are unknown. A recent Children's Oncology Group symposium considered epidemiology of obesity, pharmacology of chemotherapy and outcomes in obese adults with cancer, excess mortality in obese pediatric patients with acute myeloid leukemia (AML), and complications in obese survivors.
View Article and Find Full Text PDF